What changed?
A sourced timeline of research records and material development changes tracked by BACToBasics for Zenagamtide. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.
Tracked items
1
Research sources
0
Development entries
1
Latest recorded date
May 6, 2026
Latest development activity
May 6, 2026 · Phase advancement · Phase 3
Novo Nordisk reported that the AMAZE Phase 3 program had been initiated, advancing zenagamtide (formerly amycretin) into pivotal obesity development.
Open source ↗Tracked timeline
Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.
Phase advancement · Phase 3
Novo Nordisk reported that the AMAZE Phase 3 program had been initiated, advancing zenagamtide (formerly amycretin) into pivotal obesity development.
Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.
BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.